Effect of Avastin in Juxtafoveal Telangiectasias
Overview
Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias
Full Title of Study: “Does Avastin Change Evolution in Juxtafoveal Telangiectasias?”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Factorial Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
Detailed Description
After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.
Interventions
- Drug: Bevacizumab
- Procedure: Intravitreal injection of Bevacizumab
Clinical Trial Outcome Measures
Primary Measures
- Best corrected Visual Acuity
- Fluorescein Angiogram: Leakage
- Optical Coherence Tomography: Retinal thickness
Participating in This Clinical Trial
Inclusion Criteria
- Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion – Patients with Idiopathic Juxtafoveal Retinal Telangiectasias Exclusion Criteria:
- Diabetic Retinopathy and Diabetic Macular Edema – Hypertensive Retinopathy – Choroidal Neovascularization
Gender Eligibility: All
Minimum Age: 40 Years
Maximum Age: 70 Years
Investigator Details
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Overall Official(s)
- Veronica Kon-Jara, MD, Principal Investigator, Asociación para Evitar la Ceguera en México
- Overall Contact(s)
- Verónica Kon-Jara, MD, 5510841400, veronicakon@yahoo.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.